PRISM: A Platform Protocol for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma
Phase of Trial: Phase I
Latest Information Update: 06 Nov 2019
Price : $35 *
At a glance
- Drugs Acalabrutinib (Primary) ; Ceralasertib (Primary) ; Danvatirsen (Primary)
- Indications Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- Acronyms PRISM Study
- Sponsors Acerta Pharma
- 06 Nov 2019 Study design released at the 61st Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem 2019).
- 11 Jun 2019 Planned number of patients changed from 42 to 88.
- 13 Jun 2018 Status changed from not yet recruiting to recruiting.